Head and neck cancers are the sixth most common solid cancer worldwide, with more than 60 000 new cases per year.
1 Human papillomavirus (HPV) infection is now accepted to be a previously unrecognized cause of head and neck squamous cell carcinoma (HNSCC).
2 In the case of oropharyngeal squamous cell carcinoma (OPSCC), there has been as much as a 225% increase in HPV-positive cancers between 1988 and 2004,
3 and up to 70% of new cases are caused by HPV.
2,4,5 In general, patients with HPV-positive OPSCC use less tobacco and alcohol and are more likely to be younger than their counterparts who are negative for HPV.
3,5 HPV-positive status is associated with a significant beneficial impact on prognosis,
6-8 with 1 study reporting a 25% increase in survival at 3 years.
9 HPV-positive OPSCC responds more positively to radiotherapy, which may be associated with defects in double-strand break repair.
10-12 This improvement has led to calls for deintensified treatments,
13 which are currently being investigated.
14-16 However, investigations into non-OPSCC subsites, such as the hypopharynx, nasopharynx, oral cavity, larynx, and sinonasal cavity, are relatively scarce.